Status:
WITHDRAWN
MRI in Assessing Hypoxia in Patients With Localized Prostate Cancer Undergoing Stereotactic Body Radiation Therapy
Lead Sponsor:
University of Texas Southwestern Medical Center
Conditions:
Prostate Cancer
Eligibility:
MALE
18-120 years
Phase:
NA
Brief Summary
RATIONALE: Diagnostic procedures, such as MRI, may help measure oxygen levels in tumor cells. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURP...
Detailed Description
OBJECTIVES: * To characterize the status of global hypoxia within the prostate before stereotactic body radiotherapy (SBRT) as assessed by blood-oxygen-level-dependent and tissue-oxygen-level-depende...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Biopsy proven adenocarcinoma of the prostate
- Localized disease
- Scheduled to undergo treatment with stereotactic body radiotherapy (SBRT) on a phase II clinical trial
- Has not yet started SBRT
- PATIENT CHARACTERISTICS:
- Serum creatinine ≤ 1.2 mg/dL
- No claustrophobia
- No other contraindication to MRI (e.g., implanted pacemaker device)
- No known allergy to MRI contrast
- PRIOR CONCURRENT THERAPY:
- No prior treatment for prostate cancer (e.g., hormonal therapy or chemotherapy)
Exclusion
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00963300
Start Date
September 1 2009
End Date
September 1 2011
Last Update
November 26 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.